• New technological platform of chemical modification of acylated peptides to extend their duration of action to at least one month, AdoXLong® • Patent filing with an initial application on semaglutide, with promising in vitro and in vivo preliminary results indicating efficacy compatible with a once-monthly injection • Application to a broad range of approved and in development peptides, including GLP-1, GIP, amylin and dual/triple agonists • Adocia continues to develop BioChaperone® to stabilize and combine hormones for the treatment of diabetes and obesity, with two ongoing feasibility studies
Adocia, a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced the submission of a patent for a new long-acting peptide platform, and two feasibility studies using its BioChaperone® technology with two undisclosed pharmaceutical companies.
Launch of the new AdoXLongTM platform supported by new patent application The new AdoXLongTM platform has been developed to address a critical challenge in diabetes and obesity treatments based on GLP-1 agonists, amylin, or other metabolic peptide: long-acting formulations. Moving from weekly to monthly administration would significantly improve long-term treatment persistence, while reducing the manufacturing capacity required per patient, thereby increasing the number of patients who can be treated.
The patented technology is a long-acting peptide platform composed of a biocompatible polymer chemically linked to the peptides without modifying their mechanisms of action. Pharmaceutical products derived from this technology are low viscosity aqueous solutions compatible with standard injection devices and administered subcutaneously using 29 Gauge or smaller needles. The technology is designed to offer a long circulating peptide over at least one month.
The technology can be applied to a variety of peptides such as GLP-1, GIP, amylin, or dual/triple agonists – including semaglutide, tirzepatide, cagrilintide – with the possibility to combine these modified peptides with each other. Positive preliminary in vitro and in vivo results have been obtained with AdoXLong® applied to semaglutide.
The patent application is expected to provide worldwide protection until 2046, if granted. The peptides using the technology would also benefit from reinforced intellectual property with extension until 2046. The technology is applicable to both innovative and biosimilar peptides, including semaglutide, which will become off-patent starting in 2026 in certain territories.
Strengthening of the BioChaperone® platform with two feasibility studies with two large pharmaceutical companies
The last preclinical results obtained with BioChaperone® CagriSema were presented during the annual PODD event (Partnership Opportunities in Drug Delivery - Boston, USA, 27-28 October 2025). The Company has two ongoing feasibility studies with BioChaperone® in collaboration with two large global pharmaceutical companies whose names are not disclosed.
We have leveraged the experience and insights gained from the AdoGel® platform to adopt a different technical approach with AdoXLongTM, a promising platform targeting a patient experience as simple and comfortable as a weekly injection, while ensuring seamless integration into existing manufacturing processes. Regarding BioChaperone®, we remain confident in the value of the platform for obesity treatments, as evidenced by the two ongoing feasibility studies.
commented Olivier Soula, Chief Executive Officer and co-founder of Adocia.
For more information, read the original press release.
For more news from the world of long-acting therapeutics, sign up to the CELT's LONGEVITY mailing list here for regular updates.